<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439335</url>
  </required_header>
  <id_info>
    <org_study_id>06-0089</org_study_id>
    <nct_id>NCT00439335</nct_id>
  </id_info>
  <brief_title>Higher Dose Intradermal H5 Vaccine</brief_title>
  <official_title>A Phase I/II Randomized, Double-Blinded Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Subvirion Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle
      versus injection in the skin in healthy adults. The study will look at the safety of the
      injections, how the body reacts, and what the body's immune response does when the vaccine is
      given in the muscle versus in the skin. The study will look at 226 healthy volunteers, ages
      18-49 years old. Study procedures will include getting 2 doses of vaccine 28 days apart,
      physical exams, follow-up clinic visits to check the places on the body where each vaccine
      was given, and blood sample collections. Volunteers will complete a memory aid by writing
      down temperatures and health changes for 7 days after each vaccination. Volunteers will be
      involved in the study for up to 241 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza A viruses have the potential to cause worldwide epidemics and/or pandemics
      resulting in significant morbidity and mortality. Two-hundred twenty-six healthy male and
      female subjects aged 18 to 49 years, inclusive, in the United States (US) will be enrolled
      into this single-center, randomized, double-blinded, placebo-controlled trial of intradermal
      (ID) and intramuscular (IM) injection with subvirion (SV) inactivated influenza A/H5N1
      vaccine. The study will have two vaccine groups. Vaccine group 1: the subject will receive
      0.1 mL of H5 Hemagglutination (HA) by the ID route in one arm and 0.1 mL of saline placebo by
      the IM route in the other arm. Vaccine group 2: the subject will receive 0.1 mL of H5 HA by
      the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm. All
      eligible subjects will be enrolled and randomized 1:1 (113 subjects per vaccine group) to
      either vaccine group 1 or vaccine group 2. All subjects will receive two doses of
      approximately 30micrograms of H5 HA by their assigned route, either IM or ID, separated by
      approximately 28 days. At each vaccination visit, all subjects will also receive a saline
      placebo in the opposite arm by the different route as their vaccine route (i.e. if vaccine is
      administered by the ID route in one arm, then a saline placebo will be administered by the IM
      route in the opposite arm). The second vaccine dose will be administered by the same route as
      per vaccine group assigned at original randomization. Subjects will be observed in the clinic
      for approximately 15 minutes after each vaccination. Subjects will return on Day 2 for arm
      check and assessment of adverse events. All subjects will maintain a memory aid recording
      oral temperature, and systemic and local adverse events for 7 days after each vaccination.
      They will return to clinic on Day 8 for adverse event (AE) assessment, concomitant medication
      assessment, a targeted physical exam (if indicated), and review of memory aid. AE data will
      be captured Day 0 through Day 56. Serious AE data will be captured from Day 0 through the end
      of each subject's participation in the study (approximately 7 months). The subjects, staff
      assessing subjects, and lab personnel will be blinded. Serum for immunogenicity evaluations
      will be obtained prior to the first vaccination, at Day 0; prior to the second vaccination,
      at Day 28; on Day 56 and approximately Day 208 (7months after dose 1). The primary objectives
      are to compare the immunogenicity of a similar dosage level of a subvirion inactivated
      influenza A/H5N1 vaccine given by ID or IM injection one month after receipt of the second
      dose of vaccine and to compare the safety and reactogenicity of ID and IM immunization at a
      similar dosage level of a subvirion inactivated influenza A/H5N1 vaccine among healthy young
      adults. The secondary objective is to evaluate serum antibody responses approximately 1 and 7
      months after the first vaccination. This study is linked to Division of Microbiology and
      Infectious Diseases protocol 07-0022.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2</measure>
    <time_frame>Approximately Day 56.</time_frame>
    <description>Number of participants in each vaccine group achieving a 4-fold or greater increase in serum hemagglutination inhibition (HAI) antibody titers against influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Spontaneously Reporting Any Serious Adverse Event.</measure>
    <time_frame>Through Day 208.</time_frame>
    <description>Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Unsolicited Symptoms During a 28-day Surveillance Period Following Vaccinations at Days 0 and 28.</measure>
    <time_frame>Through approximately Day 56</time_frame>
    <description>The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 28 days of vaccination. Participants are counted only once but may have experienced events on multiple occasions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>The number of participants reporting fever, feverishness, malaise, myalgia, headache and nausea. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>The number of participants reporting pain, tenderness, itching, induration, erythema, and pigmentation. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI Geometric Mean Titer (GMT) After Dose 2</measure>
    <time_frame>Approximately Day 56.</time_frame>
    <description>HAI geometric mean titer (GMT) against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a HAI Titer of Greater Than or Equal to 40 After Dose 2</measure>
    <time_frame>Approximately Day 56</time_frame>
    <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 1.</measure>
    <time_frame>Approximately Day 28</time_frame>
    <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI GMT After Dose 1</measure>
    <time_frame>Approximately Day 28</time_frame>
    <description>HAI GMT against influenza A/H5N1 virus one month after receipt of the first dose of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 After Dose 1.</measure>
    <time_frame>Approximately Day 28</time_frame>
    <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers 7 Months After Dose 1.</measure>
    <time_frame>Approximately Day 208</time_frame>
    <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI GMT at 7 Months After Dose 1</measure>
    <time_frame>Approximately Day 208</time_frame>
    <description>HAI GMT against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 at 7 Months After Dose 1.</measure>
    <time_frame>Approximately Day 208</time_frame>
    <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 7 months after receipt of the first dose of vaccine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>H5 HA IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5 HA ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza A Vaccine A/H5N1</intervention_name>
    <description>Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.</description>
    <arm_group_label>H5 HA IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza A Vaccine A/H5N1</intervention_name>
    <description>Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.</description>
    <arm_group_label>H5 HA ID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (IM)</intervention_name>
    <description>The placebo will be 0.1 mL of saline administered by the IM route.</description>
    <arm_group_label>H5 HA ID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (ID)</intervention_name>
    <description>The placebo will be 0.1 mL of saline administered by the ID route.</description>
    <arm_group_label>H5 HA IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female between the ages of 18 and 49 years, inclusive.

          -  Women of childbearing potential (not surgically sterile or post menopausal for greater
             than or equal to 1 year) must agree to practice adequate contraception (i.e., barrier
             method, abstinence, intrauterine devices, or licensed hormonal methods) for the entire
             study period.

          -  Is in good health, as determined by vital signs (heart rate less than 100 beats per
             minute; blood pressure: systolic less than or equal to 140 mm Hg and greater than or
             equal to 90 mm Hg; diastolic less than or equal to 90 mm Hg; oral temperature less
             than 100.0 degrees Fahrenheit), medical history to ensure stable medical condition
             (see definition below) and a targeted physical examination based on medical history.

        Stable medical condition - no recent change in prescription medication, dose, or frequency
        of medication in the last 3 months and health outcomes of the specific disease are
        considered to be within acceptable limits in the last 6 months. Any change that is due to
        change of health care provider, insurance company, etc, or is done for financial reasons,
        as long as in the same class of medication, will not be considered a violation of the
        inclusion criterion. Any change to prescription medication due to improvement of a disease
        outcome will not be considered a violation of the inclusion criterion.

          -  Able to understand and comply with planned study procedures.

          -  Provides written informed consent prior to initiation of any study procedures.

        Exclusion Criteria:

          -  Has a known allergy to eggs or other components of the vaccine.

          -  Has a positive urine or serum pregnancy test prior to vaccination (if female of
             childbearing potential), is breastfeeding, or has the intention to become pregnant
             during the study period.

          -  Immunosuppression as a result of an underlying illness or treatment, or use of
             anti-cancer chemotherapy or radiation therapy within the preceding 36 months.

          -  Has an active neoplastic disease or a history of any hematologic malignancy.

          -  Long term use of oral or parenteral steroids, high-dose inhaled steroids (greater than
             800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6
             months (nasal and topical steroids are allowed).

          -  Has a history of receiving immunoglobulin or other blood product within the 3 months
             prior to vaccination in this study.

          -  Has a diagnosis of schizophrenia, Bi-polar disease or other major psychiatric
             diagnosis.

          -  Has been hospitalized for psychiatric illness, history of suicide attempt or
             confinement for danger to self or others.

          -  Is receiving psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol,
             molindone, loxapine, thioridazine, thiothixene, pimozide, fluphenazine, risperidone,
             mesoridazine, quetiapine, trifluoperazine, trifluopromazine, chlorprothixene,
             chlorpromazine, perphenazine, olanzapine, carbamazepine, divalproex sodium, lithium
             carbonate or lithium citrate). Subjects who are receiving a single antidepressant drug
             and are stable for at least 3 months prior to enrollment, without de-compensating
             symptoms will be allowed to be enrolled in the study.

          -  Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to vaccination in this study.

          -  Has an acute or chronic medical condition that, in the opinion of the investigator,
             would render vaccination unsafe or would interfere with the evaluation of responses
             (this includes, but is not limited to: known chronic liver disease, significant renal
             disease, unstable or progressive neurological disorders, diabetes mellitus, and
             transplant recipients).

          -  Has a history of severe reactions following immunization with contemporary influenza
             virus vaccines.

          -  Has a moderate to severe acute illness and/or an oral temperature greater than 100.4
             degrees Fahrenheit, within 1 week of vaccination.

          -  Known active human immunodeficiency virus, hepatitis B, or hepatitis C infection.

          -  History of alcohol or drug abuse in the 5 years prior to enrollment.

          -  Presence of any active skin disease on upper arms that could impact study product
             delivery or site assessment.

          -  Has a history of Guillain Barre syndrome.

          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or
             medication) within 1 month prior to vaccination in this study, or expects to receive
             an experimental agent during the 7-month study period.

          -  Participated in an Influenza A/H5 vaccine study in the past in a group receiving
             vaccine (but does not exclude documented placebo recipients).

          -  Is enrolled or planning to enroll in another interventional trial at any time between
             receipt of the first dose of vaccine and the end of the study (approximately 7 months
             after receipt of the first dose).

          -  Has any condition that would, in the opinion of the site investigator, place the
             subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 1;206(7):1069-77. doi: 10.1093/infdis/jis402. Epub 2012 Aug 13.</citation>
    <PMID>22891287</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>March 24, 2009</results_first_submitted>
  <results_first_submitted_qc>March 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2009</results_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, vaccine, A/H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy ambulatory adults were recruited from the surrounding community of the research clinic from March 14, 2007 to June 20, 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>H5 HA ID</title>
          <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
        </group>
        <group group_id="P2">
          <title>H5 HA IM</title>
          <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>H5 HA ID</title>
          <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
        </group>
        <group group_id="B2">
          <title>H5 HA IM</title>
          <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="7.4"/>
                    <measurement group_id="B2" value="30.5" spread="8.0"/>
                    <measurement group_id="B3" value="30.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2</title>
        <description>Number of participants in each vaccine group achieving a 4-fold or greater increase in serum hemagglutination inhibition (HAI) antibody titers against influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine</description>
        <time_frame>Approximately Day 56.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2</title>
          <description>Number of participants in each vaccine group achieving a 4-fold or greater increase in serum hemagglutination inhibition (HAI) antibody titers against influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Spontaneously Reporting Any Serious Adverse Event.</title>
        <description>Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes.</description>
        <time_frame>Through Day 208.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Spontaneously Reporting Any Serious Adverse Event.</title>
          <description>Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAI Geometric Mean Titer (GMT) After Dose 2</title>
        <description>HAI geometric mean titer (GMT) against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine.</description>
        <time_frame>Approximately Day 56.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HAI Geometric Mean Titer (GMT) After Dose 2</title>
          <description>HAI geometric mean titer (GMT) against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine.</description>
          <units>Antibody Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.3" upper_limit="34.5"/>
                    <measurement group_id="O2" value="18.1" lower_limit="13.6" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a HAI Titer of Greater Than or Equal to 40 After Dose 2</title>
        <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine</description>
        <time_frame>Approximately Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a HAI Titer of Greater Than or Equal to 40 After Dose 2</title>
          <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 28 days after receipt of the second dose of vaccine</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 1.</title>
        <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose.</description>
        <time_frame>Approximately Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 1.</title>
          <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAI GMT After Dose 1</title>
        <description>HAI GMT against influenza A/H5N1 virus one month after receipt of the first dose of vaccine.</description>
        <time_frame>Approximately Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HAI GMT After Dose 1</title>
          <description>HAI GMT against influenza A/H5N1 virus one month after receipt of the first dose of vaccine.</description>
          <units>Antibody titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="9.9" upper_limit="17.3"/>
                    <measurement group_id="O2" value="11.9" lower_limit="9.1" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 After Dose 1.</title>
        <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose of vaccine.</description>
        <time_frame>Approximately Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 After Dose 1.</title>
          <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group one month after receipt of the first dose of vaccine.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers 7 Months After Dose 1.</title>
        <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
        <time_frame>Approximately Day 208</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers 7 Months After Dose 1.</title>
          <description>Number of participants achieving a 4-fold or greater increase in HAI antibody titers against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAI GMT at 7 Months After Dose 1</title>
        <description>HAI GMT against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
        <time_frame>Approximately Day 208</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>HAI GMT at 7 Months After Dose 1</title>
          <description>HAI GMT against influenza A/H5N1 virus in each vaccine group seven months after receipt of the first dose of vaccine.</description>
          <units>Antibody Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="8.1" upper_limit="12.4"/>
                    <measurement group_id="O2" value="8.9" lower_limit="7.3" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 at 7 Months After Dose 1.</title>
        <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 7 months after receipt of the first dose of vaccine.</description>
        <time_frame>Approximately Day 208</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Serum HAI Titer of Greater Than or Equal to 40 at 7 Months After Dose 1.</title>
          <description>Number of participants achieving a serum HAI titer of greater than or equal to 40 against influenza A/H5N1 virus in each vaccine group 7 months after receipt of the first dose of vaccine.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Unsolicited Symptoms During a 28-day Surveillance Period Following Vaccinations at Days 0 and 28.</title>
        <description>The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 28 days of vaccination. Participants are counted only once but may have experienced events on multiple occasions.</description>
        <time_frame>Through approximately Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Unsolicited Symptoms During a 28-day Surveillance Period Following Vaccinations at Days 0 and 28.</title>
          <description>The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 28 days of vaccination. Participants are counted only once but may have experienced events on multiple occasions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</title>
        <description>The number of participants reporting fever, feverishness, malaise, myalgia, headache and nausea. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
        <time_frame>7 days after each vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</title>
          <description>The number of participants reporting fever, feverishness, malaise, myalgia, headache and nausea. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</title>
        <description>The number of participants reporting pain, tenderness, itching, induration, erythema, and pigmentation. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
        <time_frame>7 days after each vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H5 HA ID</title>
            <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
          </group>
          <group group_id="O2">
            <title>H5 HA IM</title>
            <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0 and 28.</title>
          <description>The number of participants reporting pain, tenderness, itching, induration, erythema, and pigmentation. Participants are counted only once for each symptom but may have experienced symptoms on multiple occasions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects recorded solicited symptoms on a memory aid for 8 days (Day 0-7) following each dose. Unsolicited non-serious adverse events were collected for 28 days after each dose and serious adverse events were collected through Day 208.</time_frame>
      <desc>The solicited symptoms are reported separately after each vaccination. The occurrence of a solicited symptom on any day(s) at any severity within the 15 day period was considered one event.</desc>
      <group_list>
        <group group_id="E1">
          <title>H5 HA ID</title>
          <description>Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.</description>
        </group>
        <group group_id="E2">
          <title>H5 HA IM</title>
          <description>Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (8.1)">Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Insulin-requiring type II diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Nausea&quot;</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Nausea&quot;</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.1)">Injection site bruising</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site desquamation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Reactogenicity event</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="541" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Erythema (redness)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Erythema (redness)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site induration (size) - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site induration (size) - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site induration (functional grading) - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; with grading based on impact on daily activities.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site induration (functional grading) - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; with grading based on impact on daily activities.</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="113"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site discolouration - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Pigmentation (discoloration)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site discolouration - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Pigmentation (discoloration)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site pruritus - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Itchiness at vaccination site&quot;</description>
                <counts group_id="E1" events="80" subjects_affected="80" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site pruritus - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Itchiness at vaccination site&quot;</description>
                <counts group_id="E1" events="83" subjects_affected="83" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site pain - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site at rest&quot;</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site pain - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site at rest&quot;</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.0)">Tenderness - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Tenderness at injection site with movement/touch&quot;</description>
                <counts group_id="E1" events="83" subjects_affected="83" subjects_at_risk="113"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.0)">Tenderness - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Tenderness at injection site with movement/touch&quot;</description>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="113"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Feeling hot - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Feverishness&quot;</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Feeling hot - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Feverishness&quot;</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Malaise - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Malaise(decreased energy)&quot;</description>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="113"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Malaise - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Malaise(decreased energy)&quot;</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="113"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema, placebo arm - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Erythema (redness)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="113"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema, placebo arm - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Erythema (redness)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="113"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site induration, placebo arm - (size) - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E2" events="112" subjects_affected="112" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site induration, placebo arm - (size) - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="113"/>
                <counts group_id="E2" events="111" subjects_affected="111" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site induration, placebo arm - (functional grading) - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; with grading based on impact on daily activities.</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" events="113" subjects_affected="113" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site induration, placebo arm - (functional grading) - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Induration (swelling)&quot; with grading based on impact on daily activities.</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="113"/>
                <counts group_id="E2" events="110" subjects_affected="110" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site discolouration, placebo arm - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Pigmentation (discoloration)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site discolouration, placebo arm - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Pigmentation (discoloration)&quot; and measured in millimeters.</description>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site pain, placebo arm - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site at rest&quot;</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site pain, placebo arm - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site at rest&quot;</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.0)">Tenderness, placebo arm - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Tenderness at injection site with movement/touch&quot;</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="113"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.0)">Tenderness, placebo arm - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Tenderness at injection site with movement/touch&quot;</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="113"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (8.1)">Myalgia - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Myalgia - (body aches not at injection site)&quot;</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Myalgia - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Myalgia - (body aches not at injection site)&quot;</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Headache&quot;</description>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="113"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Headache&quot;</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="113"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shital Patel, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-3793</phone>
      <email>shitalp@bcm.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

